Should you buy Amylin Pharmaceuticals stock? (NASDAQ:AMLN). Let's see how it does in our automated value investing analysis system.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Amylin Pharmaceuticals to reach your target.
Hmm, we can't give any reliable projection for Amylin Pharmaceuticals's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| AMLN Price (Amylin Pharmaceuticals stock price per share) |
$0.00 | |
| PE Ratio versus Sector | 100% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 100% lower than other Drug Manufacturers - General stocks | |
| Cash Yield | 0.66% | |
| Free Cash Flow Jitter | 70% |
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
Based on our analysis, we believe that you should not buy Amylin Pharmaceuticals right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Advertisement supports free stock analysis content.
Does Amylin Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to AMLN: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles